NCT05697406 HP Pyruvate MRI in Cancers
| NCT ID | NCT05697406 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | University of Maryland, Baltimore |
| Condition | Image |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 25 participants in total. It began in 2024-06-24 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.
Eligibility Criteria
Inclusion Criteria: Clinical tumor diagnosis Patients with pre-existing MR imaging appointments Must be able to undergo MR Exclusion Criteria: No tumor diagnosis
Frequently Asked Questions
Who can join the NCT05697406 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 88 Years, studying Image. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05697406 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05697406 currently recruiting?
Yes, NCT05697406 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Maryland, Baltimore to inquire about joining.
Where is the NCT05697406 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT05697406 clinical trial?
NCT05697406 is sponsored by University of Maryland, Baltimore. The trial plans to enroll 25 participants.